2026-04-18T03:00:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/705972025-06-04T00:15:01Zcom_2072_6col_2072_452952

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort Herrera Hidalgo, Laura Muñoz, Patricia Álvarez-Uría, Ana Alonso-Menchén, David Luque Márquez, Rafael Gutiérrez Carretero, Encarnación Fariñas, Mari Carmen Miró, José María Goenaga, Miguel Angel López-Cortés, Luis E. Angulo-Lara, Basilio Boix Palop, Lucía Alarcón, Arístides de Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) Cohort Investigators Antistaphylococcal penicillin Cefazolin Infective endocarditis Methicillin-susceptible Staphylococcus aureus Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors.Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective. 2025-06-04T00:15:01Z 2025-06-04T00:15:01Z 2025-06-04T00:15:01Z 2025-06-03T06:11:58Z 2025-06-03T06:11:58Z 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/10230/70597 Int J Infect Dis. 2023 Dec;137:134-43 © 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Elsevier